1. Home
  2. CYTH vs TACT Comparison

CYTH vs TACT Comparison

Compare CYTH & TACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTH
  • TACT
  • Stock Information
  • Founded
  • CYTH 1990
  • TACT 1996
  • Country
  • CYTH United States
  • TACT United States
  • Employees
  • CYTH N/A
  • TACT N/A
  • Industry
  • CYTH Biotechnology: Pharmaceutical Preparations
  • TACT Computer peripheral equipment
  • Sector
  • CYTH Health Care
  • TACT Technology
  • Exchange
  • CYTH Nasdaq
  • TACT Nasdaq
  • Market Cap
  • CYTH 35.5M
  • TACT 37.5M
  • IPO Year
  • CYTH N/A
  • TACT 1996
  • Fundamental
  • Price
  • CYTH $1.21
  • TACT $3.90
  • Analyst Decision
  • CYTH Strong Buy
  • TACT Strong Buy
  • Analyst Count
  • CYTH 3
  • TACT 1
  • Target Price
  • CYTH $3.20
  • TACT $7.50
  • AVG Volume (30 Days)
  • CYTH 27.4K
  • TACT 11.0K
  • Earning Date
  • CYTH 08-12-2024
  • TACT 08-07-2024
  • Dividend Yield
  • CYTH N/A
  • TACT N/A
  • EPS Growth
  • CYTH N/A
  • TACT N/A
  • EPS
  • CYTH N/A
  • TACT 0.06
  • Revenue
  • CYTH $1,126,444.00
  • TACT $61,048,000.00
  • Revenue This Year
  • CYTH $28.30
  • TACT N/A
  • Revenue Next Year
  • CYTH $14.19
  • TACT $21.64
  • P/E Ratio
  • CYTH N/A
  • TACT $65.00
  • Revenue Growth
  • CYTH N/A
  • TACT N/A
  • 52 Week Low
  • CYTH $0.89
  • TACT $3.32
  • 52 Week High
  • CYTH $2.12
  • TACT $8.80
  • Technical
  • Relative Strength Index (RSI)
  • CYTH 45.15
  • TACT 54.92
  • Support Level
  • CYTH $1.13
  • TACT $3.76
  • Resistance Level
  • CYTH $1.28
  • TACT $3.98
  • Average True Range (ATR)
  • CYTH 0.07
  • TACT 0.18
  • MACD
  • CYTH -0.01
  • TACT 0.04
  • Stochastic Oscillator
  • CYTH 5.00
  • TACT 81.82

About CYTH Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

About TACT TransAct Technologies Incorporated

Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

Share on Social Networks: